Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
暂无分享,去创建一个
Xiuli Wu | J. Gregg | R. Cardiff | L. Young | A. Borowsky | K. Carraway | Colin A. Baron | L. Yen | Ellen Q Ingalla | C. Sweeney | Zhongwei Cao
[1] J. Segall,et al. ErbB3-dependent motility and intravasation in breast cancer metastasis. , 2006, Cancer research.
[2] Roger L. Williams,et al. Phosphoinositide 3-kinases as drug targets in cancer. , 2005, Current opinion in pharmacology.
[3] A. Thor,et al. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells , 2005, Breast Cancer Research.
[4] S. Wiseman,et al. Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival , 2005, Cancer.
[5] Ken Jacobson,et al. MAP kinases and cell migration , 2004, Journal of Cell Science.
[6] A. Goldberg,et al. Nrdp1‐mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis , 2004, The EMBO journal.
[7] K. Carraway,et al. Negative regulation of ErbB family receptor tyrosine kinases , 2004, British Journal of Cancer.
[8] I. Bièche,et al. Prognostic value of ERBB family mRNA expression in breast carcinomas , 2003, International journal of cancer.
[9] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[10] J. R. Reeves,et al. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.
[11] J. Koland,et al. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling. , 2003, Experimental cell research.
[12] A. Citri,et al. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.
[13] H. Esumi,et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. , 2002, Molecular biology of the cell.
[14] A. Goldberg,et al. Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Neve,et al. Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells , 2002, Oncogene.
[16] K. M. Nicholson,et al. The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.
[17] K. Carraway,et al. An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[18] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[19] M. Cobb,et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.
[20] M. Karin,et al. Mammalian MAP kinase signalling cascades , 2001, Nature.
[21] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[22] Y. Chiew,et al. Expression of c‐erbB receptors, heregulin and oestrogen receptor in human breast cell lines , 2000, International journal of cancer.
[23] Jie Leng,et al. ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by Erbb Family Receptor Tyrosine Kinases , 2000, The Journal of cell biology.
[24] R. Lupu,et al. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. , 1999, International journal of oncology.
[25] Y. Shimizu,et al. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. , 1999, Molecular biology of the cell.
[26] R. Cardiff,et al. Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.
[27] L. Cantley,et al. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[28] Dihua Yu,et al. Heregulin β1-activated Phosphatidylinositol 3-Kinase Enhances Aggregation of MCF-7 Breast Cancer Cells Independent of Extracellular Signal-regulated Kinase , 1999 .
[29] Kuala Lumpur Malaysia,et al. Expression of c-erbB3 protein in primary breast carcinomas. , 1998, British Journal of Cancer.
[30] P. W. Janes,et al. Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells , 1998, Oncogene.
[31] D. Stern,et al. Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[32] R. Whitaker,et al. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] Y. Yarden,et al. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.
[34] R. Mulligan,et al. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[35] Y. Yarden,et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.
[36] A. Ullrich,et al. Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.
[37] H. Earp,et al. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research , 1995, Breast Cancer Research and Treatment.
[38] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[39] M. Kraus,et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.
[40] N. Hynes,et al. The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.
[41] L. Cantley,et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[42] L. Cantley,et al. A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling , 1994, Cell.
[43] Y. Yarden,et al. A single autophosphorylation site confers oncogenicity to the Neu/ErbB‐2 receptor and enables coupling to the MAP kinase pathway. , 1994, The EMBO journal.
[44] R Akita,et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. , 1993, Cancer research.
[45] D. Barnes,et al. Expression of the ERBB3 gene product in breast cancer. , 1992, British Journal of Cancer.
[46] K. Kuroi,et al. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. , 1992, American journal of surgery.
[47] Y. Yarden,et al. Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation. , 1992, The Journal of biological chemistry.
[48] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.
[49] John F. Timms,et al. Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer , 2001 .
[50] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.